We previously demonstrated the significance of constitutive activation of BCR signaling pathways in promoting proliferation of CLL cells, highlighting efficacy of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in abrogating leukemic advancement even in pre-leukemic stages38. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.